US-Listed China Biotech Shares Hit By Broad China Cybersecurity Review
Over-Valuation Correction As Well?
First DIDI, then other recently US-listed tech companies and now biotech companies are seeing share drops as China widens its cybersecurity reviews. But investors are also seeing other corrections from recent highs.
